Sign In
Stocks
News
ETFs
Economy
Currencies
Press Releases
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
Published a year ago
via
GlobeNewswire